rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PCRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pacira BioSciences completes merger with Viatris and announces Nasdaq delisting
      Nov 17Investing.comPCRXVTRS
      VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook
      Nov 10Yahoo FinancePCRX
      Pacira’s final earnings in spotlight before $1.65B sale
      Nov 8Investing.comPCRX
      Pacira earnings missed by $0.03, revenue fell short of estimates
      Nov 8Investing.comPCRX
      Viatris Inc (VTRS) (Q3 2026) Earnings Call Highlights: Raised Guidance, Pacira Deal and Supply ...
      Nov 5Yahoo FinancePCRXVTRS
      Viatris Begins $36.50 Per Share Cash Offer for Pacira BioSciences
      Oct 30Yahoo FinancePCRXVTRS
      Viatris launches tender offer for Pacira at $36.50 per share
      Oct 30Investing.comPCRXVTRS
      Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
      Oct 30Yahoo FinancePCRX
      Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
      Oct 29Yahoo FinancePCRX
      Pacira earnings in focus as Viatris deal nears completion
      Oct 28Investing.comPCRXVTRS
      ETFs Are Net Sellers of Pacira BioSciences (PCRX) on Oct. 22

      Six ETFs sold $10.5 million of Pacira BioSciences stock in Thursday's session.

      Oct 26Yahoo FinancePCRX
      Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing
      Oct 23Yahoo FinancePCRXVTRS
      Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Pacira Pharmaceuticals (PCRX)

      Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailPCRX
      Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade) (NASDAQ:VTRS)
      Oct 12Seeking AlphaPCRXVTRS
      Pacira BioSciences SVP Riker sells $217,920 stock
      Oct 12Investing.comPCRX
      Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
      Oct 12Yahoo FinancePCRXVTRSKO
      SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
      Oct 11MorningstarPCRX
      Pacira BioSciences SVP Lauren Riker sells $217,920 in stock
      Oct 11Investing.comPCRX
      Pacira BioSciences SVP Lauren Riker sells $217,920 in stock
      Oct 10Investing.comPCRX
      Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock
      Oct 9Investing.comPCRX
      Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
      Oct 9Yahoo FinancePCRXVTRS
      Pacira to be acquired by Viatris in cash deal

      Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailPCRXVTRS
      Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

      VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

      Oct 9Yahoo FinancePCRXVTRS
      Viatris to Acquire Pacira, Expanding Non-Opioid Portfolio

      Detailed price information for Viatris Inc (VTRS-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailPCRXVTRS
      Viatris To Acquire Pacira BioSciences - What Investors Should Know (NASDAQ:VTRS)

      Viatris is acquiring Pacira Biosciences to boost its pain management portfolio and address revenue stagnation. Read why VTRS stock is upgraded to a hold.

      Oct 9Seeking AlphaPCRXVTRS
      Oppenheimer Downgrades Pacira Biosciences to Perform From Outperform on Heels of Announced Sale to Viatris
      Oct 9Yahoo FinancePCRX
      HC Wainwright Downgrades Pacira Biosciences to Neutral, Price Target is $36.50
      Oct 9Yahoo FinancePCRX
      Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
      Oct 9Yahoo FinancePCRXVTRS
      Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)

      Pacira BioSciences (PCRX) stock surged 44% after Viatris’ $36.50/share buyout deal.

      Oct 8Seeking AlphaPCRXVTRS
      Atomic Machines gets $250M, Viatris pays $1.65B for Pacira, Balerion raises $200M for space bets
      Oct 8AxiosPCRX
      Jefferies downgrades Pacira Pharmaceuticals stock rating on Viatris deal
      Oct 8Investing.comPCRXVTRS
      Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout
      Oct 8Yahoo FinancePCRXVTRS
      12 Health Care Stocks Moving In Thursday's Intraday Session - Pacira BioSciences (NASDAQ:PCRX), Onconetix

      Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose 34.2% to

      Oct 8BenzingaONCOPCRX
      Why Is Pacira BioSciences Stock Skyrocketing Thursday? - Viatris (NASDAQ:VTRS), Pacira BioSciences (NASDA

      Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.

      Oct 8BenzingaPCRXVTRS
      PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
      Oct 8MorningstarPCRX
      Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal
      Oct 8Yahoo FinancePCRXVTRS
      Viatris Focuses on Non-Opioid Painkillers With Pacira BioSciences Acquisition
      Oct 8Barron'sPCRXVTRS
      Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

      The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

      Oct 8Yahoo FinancePCRXVTRS
      Why Pacira BioSciences Skyrocketed Today | The Motley Fool

      The specialty pharmaceutical company is being acquired.

      Oct 8The Motley FoolPCRX
      Small Biotech Catapults On $1.65 Billion Takeover Deal

      Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

      Oct 8Investor's Business DailyPCRXVTRS
      Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal
      Oct 8ReutersPCRXVTRS
      Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion
      Oct 8Yahoo FinancePCRXVTRS
      Pacira Pharmaceuticals stock hits 52-week high at 36.32 USD
      Oct 8Investing.comPCRX
      Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving H

      U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.

      Oct 8BenzingaHELEPCRXWOLF
      Why is Pacira BioSciences stock surging today?
      Oct 8Investing.comPCRX
      Viatris to Buy Pacira BioSciences for $1.65 Billion
      Oct 8WSJPCRXVTRS
      Viatris to Acquire Pacira BioSciences for $1.65 Billion
      Oct 8Yahoo FinancePCRXVTRS
      Needham Downgrades Pacira Biosciences to Hold From Buy
      Oct 8Yahoo FinancePCRX
      JPMorgan Upgrades Pacira Biosciences to Neutral From Underweight, $36.50 Price Target
      Oct 8Yahoo FinancePCRX
      Jefferies Downgrades Pacira Biosciences to Hold From Buy, $36 Price Target
      Oct 8Yahoo FinancePCRX

      This is the newest page. Registered accounts read further back.